Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

NMOSD and MOG Antibody-Associated Disease

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease of the central nervous system, often misdiagnosed as multiple sclerosis; aquaporin-4 antibodies (AQP4-IgG) confirm the diagnosis and have enabled targeted therapy [S10] [S11]. MOG antibody-associated disease (MOGAD) is a distinct entity with a different course and treatment response [S9]. Optic neuritis is the most common manifestation of NMOSD and can cause rapid, severe and sometimes bilateral loss of vision with frequent sequelae [S11].

Key points - Treat an NMOSD attack as an emergency with intravenous corticosteroids and plasma exchange, without waiting for antibody confirmation [S11]. - Long-term relapse prevention is essential in NMOSD; RCTs show that eculizumab, inebilizumab, satralizumab and rituximab reduce relapses [S1] [S2] [S3] [S4]. - Where biologics are not accessible, conventional immunosuppressants remain alternatives [S10]; rituximab appears more effective than mycophenolate as first-line therapy [S6]. - MOGAD attacks are often very responsive to high-dose intravenous corticosteroids, but relapses occur in more than 40% of adults after 5 years [S9]. - NMOSD is more frequent in Asian and African populations than in European ones, yet data from Africa are scarce [S7].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Severe or bilateral optic neuritis, with a risk of very low long-term acuity in NMOSD [S11].
• Longitudinally extensive, centrally located spinal cord lesions (myelitis), which may lead to tetraplegia [S11].
• Area postrema syndrome: nausea, vomiting and severe hiccups that resist conventional treatment [S11].
• Pregnancy and the postpartum period: NMOSD pregnancy is high risk and attack risk increases after delivery [S11].
• Misdiagnosis as multiple sclerosis [S10].

Recognise it

NMOSD - MRI shows extensive optic nerve lesions, mostly in the posterior part of the nerve and sometimes reaching the chiasm [S11]. - At least two thirds of cases are associated with AQP4-IgG [S1]. - In an African systematic review (19 studies, 410 cases in 10 of 54 countries), mean age at diagnosis was 33 years and 75% were female; transverse myelitis followed by optic neuritis were the most frequent presenting symptoms [S7].

MOGAD - MOGAD affects adults and children, more often children [S9]. - Children under 10 often present with acute disseminated encephalomyelitis; older children and adults more often present with unilateral or bilateral optic neuritis or myelitis [S9]. - MRI clues: extensive anterior optic nerve involvement, perineuritis, and spinal cord lesions involving the conus [S9]. - Visual and other sequelae occur much less often than in NMOSD [S9].

Confirm it

• MENACTRIMS (2026, regional consensus for the Middle East and North Africa) endorses the 2015 International Panel criteria and AQP4-IgG testing by cell-based assay [S10].
• Consider multiple sclerosis, MOGAD and acute disseminated encephalomyelitis in the differential [S10].
• MOGAD is confirmed by serum anti-MOG antibodies; if in doubt, confirm in a reference laboratory [S9].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

1. Suspect NMOSD in severe optic neuritis, myelitis or intractable hiccups and vomiting [S11]. Attacks are an emergency: arrange immediate transfer to a centre able to give intravenous corticosteroids and plasma exchange [S11].
2. In known NMOSD, do not stop maintenance therapy without specialist advice; prevention of relapses limits disability [S11].

Tier B (general eye clinic)

1. Document acuity and fields; involve neurology. Follow-up is multidisciplinary [S11] [S9].
2. Start treatment without waiting for antibody results when an NMOSD attack is suspected [S11]; send AQP4-IgG and MOG-IgG [S10] [S9].
3. Doses of steroids are not given in these abstracts: follow local protocols.

Tier C (specialist centre)

Acute attacks 1. NMOSD: prompt high-dose intravenous methylprednisolone, with early plasma exchange for severe or steroid-refractory attacks [S10]; the French guideline advises corticosteroids and plasma exchange for attacks [S11]. - Timing evidence conflicts. A meta-analysis of 8 observational studies (228 patients) found plasma exchange reduced EDSS by -1.04 and suggested an optimal start 8 to 23 days after onset; 20.8% had adverse events [S5]. Guidelines favour early use [S10] [S11]. 2. MOGAD: high-dose intravenous corticosteroids followed by an oral taper [S9]. A 2026 meta-analysis (10 publications, 1045 patients) found plasmapheresis associated with improved logMAR acuity (mean difference 1.43) in optic neuritis and an excellent recovery rate of 81%, with adverse effects in 3%; heterogeneity was high and RCTs are needed [S12].

NMOSD relapse prevention (RCT evidence) 3. Eculizumab (PREVENT, 143 AQP4-positive adults): relapses in 3% vs 43% with placebo (hazard ratio 0.06); no significant difference in disability; one death from pulmonary empyema [S1]. Dose as reported in [S1]: 900 mg weekly for 4 doses, then 1200 mg every 2 weeks. Industry-funded. 4. Inebilizumab (N-MOmentum, 230 participants, 25 countries): attacks in 12% vs 39% (hazard ratio 0.272); stopped early for efficacy [S2]. Industry-funded. 5. Satralizumab added to immunosuppressants (83 patients): relapse in 20% vs 43% (hazard ratio 0.38); in AQP4-positive patients 11% vs 43%, in AQP4-negative patients 36% vs 43% (not significant) [S3]. Industry-funded. 6. Rituximab (RIN-1, Japan, 38 AQP4-positive patients): no relapses vs 7 (37%) with placebo over 72 weeks; small trial with mild disease activity [S4]. 7. Choice of agent: monoclonal antibodies (rituximab, inebilizumab, eculizumab, ravulizumab, satralizumab or tocilizumab) according to availability and patient factors; conventional immunosuppressants when biologics are inaccessible [S10]. Azathioprine or mycophenolate are less used first-line but remain possible [S11]. In a meta-analysis of 919 patients, relapse risk was higher with mycophenolate than rituximab (hazard ratio 1.55); azathioprine vs rituximab was not significantly different (1.42) [S6]. 8. Pregnancy: plan after 12 months or more of disease stability and resume treatment early after delivery [S10].

MOGAD relapse prevention 9. Long-term therapy may be proposed, particularly after a relapse, after discussion with a reference centre [S9]. A meta-analysis of mainly retrospective studies found relapse-free proportions of 65% with azathioprine, 73% mycophenolate, 66% rituximab, 79% maintenance IVIG and 93% tocilizumab [S8].

Low-resource note: in Africa, relapses were treated with intravenous methylprednisolone and azathioprine with steroids were the most used maintenance treatments; outcomes were rarely reported [S7].

Refer when

Pitfalls

• Waiting for antibody results before treating an NMOSD attack [S11].
• Labelling NMOSD as multiple sclerosis [S10].
• Assuming satralizumab works equally in AQP4-negative disease; the subgroup difference was not significant [S3].
• Assuming MOGAD is always monophasic: adult relapse risk exceeds 40% at 5 years [S9].

Evidence notes

• Conflict: guidelines advise early plasma exchange [S10] [S11], while an observational meta-analysis reported greater EDSS reduction when started 8 to 23 days after onset [S5]. The abstract does not explain the difference; early use remains guideline advice.
• The four biologic RCTs used placebo comparators and three were industry-funded [S1] [S2] [S3]; there are no head-to-head trials in these sources.
• MOGAD treatment evidence is observational [S8] [S12].
• Not covered by these sources: cost and access to biologics, vaccination and infection screening before immunotherapy, steroid doses, and ravulizumab or tocilizumab trial data.

Related articles

• Optic Neuritis

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.